Enzo Biochem, Inc. (NYSE:ENZ) CEO Elazar Rabbani sold 14,000 shares of the business’s stock in a transaction that occurred on Wednesday, January 17th. The stock was sold at an average price of $7.75, for a total value of $108,500.00. Following the sale, the chief executive officer now directly owns 1,867,202 shares in the company, valued at $14,470,815.50. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink.

Elazar Rabbani also recently made the following trade(s):

  • On Wednesday, October 25th, Elazar Rabbani sold 72,401 shares of Enzo Biochem stock. The stock was sold at an average price of $10.09, for a total value of $730,526.09.

Shares of Enzo Biochem, Inc. (ENZ) opened at $7.96 on Monday. Enzo Biochem, Inc. has a 52 week low of $6.27 and a 52 week high of $12.04. The firm has a market capitalization of $373.53, a P/E ratio of -199.00 and a beta of 0.87.

Enzo Biochem (NYSE:ENZ) last issued its quarterly earnings data on Thursday, December 7th. The medical research company reported ($0.01) earnings per share for the quarter, hitting the Thomson Reuters’ consensus estimate of ($0.01). Enzo Biochem had a negative return on equity of 1.89% and a negative net margin of 1.53%. The company had revenue of $27.68 million for the quarter, compared to analysts’ expectations of $27.51 million. equities analysts anticipate that Enzo Biochem, Inc. will post -0.02 EPS for the current fiscal year.

Separately, TheStreet cut Enzo Biochem from a “b” rating to a “c+” rating in a research note on Wednesday, September 27th.

Several institutional investors and hedge funds have recently added to or reduced their stakes in the company. Evermore Global Advisors LLC grew its stake in shares of Enzo Biochem by 3.7% during the third quarter. Evermore Global Advisors LLC now owns 3,685,520 shares of the medical research company’s stock valued at $38,587,000 after buying an additional 130,287 shares during the last quarter. Dimensional Fund Advisors LP grew its stake in shares of Enzo Biochem by 6.0% during the third quarter. Dimensional Fund Advisors LP now owns 2,148,017 shares of the medical research company’s stock valued at $22,490,000 after buying an additional 121,370 shares during the last quarter. Renaissance Technologies LLC grew its stake in shares of Enzo Biochem by 1.3% during the second quarter. Renaissance Technologies LLC now owns 2,069,600 shares of the medical research company’s stock valued at $22,848,000 after buying an additional 27,200 shares during the last quarter. Vanguard Group Inc. grew its stake in shares of Enzo Biochem by 5.2% during the second quarter. Vanguard Group Inc. now owns 1,752,680 shares of the medical research company’s stock valued at $19,350,000 after buying an additional 86,922 shares during the last quarter. Finally, State Street Corp grew its stake in shares of Enzo Biochem by 14.4% during the second quarter. State Street Corp now owns 667,535 shares of the medical research company’s stock valued at $7,373,000 after buying an additional 84,043 shares during the last quarter. 63.66% of the stock is currently owned by hedge funds and other institutional investors.

TRADEMARK VIOLATION NOTICE: “Elazar Rabbani Sells 14,000 Shares of Enzo Biochem, Inc. (ENZ) Stock” was originally reported by Watch List News and is the property of of Watch List News. If you are reading this piece of content on another site, it was stolen and republished in violation of US & international trademark and copyright law. The original version of this piece of content can be viewed at https://www.watchlistnews.com/elazar-rabbani-sells-14000-shares-of-enzo-biochem-inc-enz-stock/1817889.html.

Enzo Biochem Company Profile

Enzo Biochem, Inc is a bioscience company focusing on delivering and applying technology capabilities to produce products and services. The Company’s segments include Enzo Clinical Labs, Enzo Life Sciences and Enzo Therapeutics. Enzo Clinical Labs is a clinical reference laboratory providing a range of clinical services to physicians, medical centers, other clinical labs and pharmaceutical companies.

Receive News & Ratings for Enzo Biochem Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Enzo Biochem and related companies with MarketBeat.com's FREE daily email newsletter.